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Cell replacement therapy using embryonic stem cells (ESCs) and induced pluripotent stem
cells (iPSCs) is a promising strategy for the treatment of neurologic diseases such as
Parkinson’s disease (PD). However, a limiting factor for effective cell transplantation is
the low survival rate of grafted cells, especially neurons. In this study, we modified the
host environment and investigated whether the simultaneous administration of soluble
factors can improve the survival and differentiation of murine iPSC-derived dopaminergic
(DA) neurons in host brains. With the goal of applying this technology in clinical settings in
the near future, we selected drugs that were already approved for clinical use. The drugs
included two commonly used anti-convulsants, valproic acid (VPA) and zonisamide (ZNS),
and estradiol (E2), also known as biologically active estrogen. Following neural induction of
murine iPSCs, we collected neural progenitor cells (NPCs) by sorting PSA-NCAM+ cells,
then treated the PSA-NCAM+ cells with drugs for 4 days. An immunofluorescence study
revealed that 0.01mM and 0.1mM of VPA and 10nM of E2 increased the percentage
of tyrosine hydroxylase+ (TH: a DA neuron marker) cells in vitro. Furthermore, 0.1mM
of VPA increased the percentage of TH+ cells that simultaneously express the midbrain
markers FOXA2 and NURR1. Next, in order to determine the effects of the drugs in vivo,
the iPSC-derived NPCs were transplanted into the striata of intact SD rats. The animals
received intraperitoneal injections of one of the drugs for 4 weeks, then were subjected to
an immunofluorescence study. VPA administration (150mg/kg/daily) increased the number
of NeuN+ post-mitotic neurons and TH+ DA neurons in the grafts. Furthermore, VPA
(150mg/kg/daily) and ZNS (30mg/kg/daily) increased the number of TH+FOXA2+ midbrain
DA neurons. These results suggest that the systemic administration of VPA and ZNS may
improve the efficiency of cell replacement therapy using iPSCs to treat PD.
Keywords: induced pluripotent stem cells, valproic acid, zonisamide, estradiol, transplantation, dopaminergic
neurons
INTRODUCTION
Parkinson’s disease (PD) is a progressive neurodegenerative dis-
order characterized by a loss of nigrostriatal dopaminergic (DA)
neurons. In several clinical studies, the transplantation of fetal
midbrain cells has successfully improved the motor symptoms of
many PD patients, thus implying that cell replacement therapy is
a promising strategy for the treatment of PD (Freed et al., 2001;
Olanow et al., 2003; Mendez et al., 2005). More recently, pluripo-
tent stem cells, especially induced pluripotent stem cells (iPSCs),
have attracted much attention as a new source of donor cells
due to their potential to supply a large quantity of DA neurons.
However, iPSC-derived DA neurons and their precursors survive
poorly in host brains (Hargus et al., 2010; Rhee et al., 2011).
Furthermore, the procedure requires modification to improve the
number as well as the quality of DA neurons in transplants to
achieve the maximum efficacy of the therapy.
In the present study, we aimed to determine whether simul-
taneous administration of soluble factors can improve the sur-
vival and differentiation of murine iPSC-derived DA neurons in
host brains. With the goal of applying this technology in clin-
ical settings in the near future, we only used factors that were
already approved for clinical use. Furthermore, candidate fac-
tors must cross the blood-brain barrier and diffuse into the brain
parenchyma. Therefore, we selected two commonly used anti-
convulsant drugs, valproic acid (VPA) and zonisamide (ZNS).
We also selected estradiol (E2), also known as biologically active
estrogen, an important female sex hormone that is widely used
to treat patients suffering from ovarian deficiency symptoms,
menopausal disorders, and osteoporosis.
ZNS has been shown to be neuroprotective in 6-OHDA-
(Asanuma et al., 2010) and MPTP-lesioned mice (Yano
et al., 2009; Sonsalla et al., 2010; Choudhury et al., 2011).
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Neuroprotective effects against MPTP toxicity are also observed
with 17β-E2 (Dluzen et al., 1996, 2001; Miller et al., 1998;
Callier et al., 2001; Ramirez et al., 2003) and VPA (Kidd and
Schneider, 2010, 2011). Furthermore, these compounds are also
advantageous in cell transplantation studies using neural pro-
genitor cells (NPCs). A study by Abematsu et al. demonstrated
remarkable improvement of the hind limb function in a mouse
model of spinal cord injury after NPC transplantation with
VPA treatment, which favors NPC differentiation toward neu-
rons rather than glial cells (Abematsu et al., 2010). E2 increases
the proportion of human NPC-derived DA neurons in vitro
and in vivo, thus suggesting that it promotes DA differentiation
and supports the survival of mature DA neurons (Kishi et al.,
2005).
Based on these previous studies, we investigated whether
VPA, ZNS, or E2 affects the differentiation of DA neurons
derived from murine iPSCs in vitro. We then evaluated their
effects in vivo by grafting the iPSC-derived NPCs into the stri-
ata of rats that received daily injections of one of the test
compounds.
MATERIALS AND METHODS
DIFFERENTIATION OF DOPAMINERGIC NEURONS FROMMURINE iPS
CELLS
Amurine iPS line 440A-3 (a gift fromDr. Okita, Kyoto University
Center for iPS Cell Research and Application, Kyoto, Japan)
was used after 10–25 passages. Generated with a plasmid vector
containing three genes, Oct3/4, Klf4, and Sox2, the 440A3 cells
carried the green fluorescence protein (GFP) and the puromycin-
resistance gene under the Nanog enhancer and promoter, which
are only active when the cells are in an undifferentiated state
(Okita et al., 2008). No integration of the exogene was reported.
Undifferentiated cells were maintained on mitomycin
C-treated murine embryonic fibroblast (MEF) feeder cells
in DMEM (Wako) supplemented with 1% fetal calf serum,
5% knockout serum replacement (KSR; Invitrogen), 0.1mM
of non-essential amino acids, 1mM of sodium pyruvate,
0.1mM of 2-mercaptoethanol (2-ME; Invitrogen), 2000U/ml
of leukemia inhibitory factor (Invitrogen), and 1.5μg/ml
of puromycin (Takara) to eliminate differentiated cells. For
neural induction of iPS cells, we used the serum-free culture
of embryoid body-like aggregates (SFEB) method (Watanabe
et al., 2005). Briefly, 440A3 cells were dissociated with 0.25%
trypsin/1 mM EDTA and seeded onto 96-well low-adhesion
plates (Lipidure-Coat Plate A-U96, NOF Corporation) at
a density of 3000 cells/well to induce re-aggregation on
day 0 in differentiation medium containing GMEM with
5% KSR, 0.1mM of non-essential amino acids, 1mM of
sodium pyruvate, and 0.1mM of 2-ME. During the dif-
ferentiation period, various factors were added to induce
the midbrain DA phenotype, as indicated in Figure 1A:
20 ng/ml of murine FGF-8b (R&D Systems) from days 3 to
7, 10 ng/ml of recombinant murine sonic hedgehog (C25II)
N-terminus (R&D Systems) from days 4 to 7, 1% N-2
Supplement (Gibco) and 200 nM of ascorbic acid from day
7 onwards. KSR was withdrawn from the differentiation medium
on day 7.
FLUORESCENCE-ACTIVATED CELL SORTING (FACS)
On day 9, 440A3 cells were rinsed twice in PBS(–) and disso-
ciated into single cells using a 5-min incubation with Accumax
(Innovate Cell Technologies) at 37◦C. The cells were collected
with a FACS buffer consisting of PBS(–) with 2% FBS, 20mM
of D-glucose and 1% Penicillin/Streptomycin (P/S, Invitrogen),
and mechanically dissociated into a single cell suspension by gen-
tle pipetting. Subsequently, the cells were incubated with murine
anti-PSA-NCAM antibodies (1:200, Millipore) for 30min at 4◦C
and washed twice by centrifugation, followed by another 30-
min incubation with the secondary antibody AlexaFluor 594
donkey anti-mouse IgG (1:400, Invitrogen). Dead cells and
debris were excluded using 7-aminoactionomycin-D (7-AAD, BD
Pharmingen) staining, and the viable cells were again suspended
at a final concentration of 1 × 107 cells/ml. Cell sorting was
performed using a FACSAriaII cell sorter (Becton Dickinson)
equipped with 488-nm argon and 633-nm Helium-Neon lasers,
a 100-μm nozzle, and the FACSDiva software program. PSA-
NCAM positivity was determined according to the negative
control lacking the primary antibody.
In vitro TREATMENT OF DOPAMINERGIC PROGENITORS WITH TEST
COMPOUNDS
After cell sorting, the PSA-NCAM+ population was seeded onto
96-well plates at a density of 20,000 cells/well in DMEM/F12
medium (Wako) supplemented with 1% N-2 Supplement,
200 nM of ascorbic acid, 2% B27 Supplement (Invitrogen),
0.5mM of L-glutamine, and 1% P/S to induce re-aggregation.
The ROCK inhibitor Y-27632 (Wako) was used during the sort-
ing procedure and the following overnight culture at 30μM to
prevent apoptosis (Koyanagi et al., 2008). On day 10, either VPA
(Sigma), ZNS sodium salt (provided by Dainippon Sumitomo
Pharma, Osaka, Japan), 17β E2 (Sigma), GDNF (R&D Systems),
or PBS(–) was added to the culture for 4 days. VPA, ZNS, and
E2 were each used at three different concentrations: 0.01mM,
0.1mM, and 1mM for VPA, 1μM, 10μM, and 100μM for
ZNS, and 1 nM, 10 nM, and 100 nM for E2. GDNF was added
at 20mg/ml to provide a positive control. To antagonize the
effects of VPA and E2, either an adenylate cyclase inhibitor
2,5-dideoxyadenosine (ddA, 100μM; Santa Cruz Biotechnology)
or an estrogen receptor antagonist ICI182780 (ICI, 2μM; Wako)
was added to the culture medium on day 10.
TRANSPLANTATION STUDY
Ten-week-old male Sprague–Dawley rats (Shimizu Laboratory
Supplies, Kyoto, Japan) were cared for and handled according
to the Guidelines for Animal Experiments of Kyoto University.
The animals were anesthetized and injected stereotactically with
the donor cells in the bilateral striatum (from the bregma:
A +1.0mm; R or L +3.0mm; V +4.5mm). For each tract, two
aggregations of the day 9 population containing 3.1 × 105 cells on
average were collected in 1μl PBS(–) supplemented with 30μM
of Y-27632 and used for transplantation. Intraperitoneal injec-
tions of VPA (150mg/kg/day), ZNS sodium salt, (30mg/kg/day),
E2 (80μg/kg/day), or saline were administered 2 days in
advance of the procedure and continued until the day of sac-
rifice. All animals also received a daily dose of 10mg/kg of
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FIGURE 1 | Generation of dopaminergic neurons from murine iPSCs.
(A) Murine iPSCs (440A3) were induced to differentiate into DA neurons via
the SFEBq method with the addition of various factors during 14 days of
suspension culture. (B) Phase contrast images (upper) and fluorescent
images for nanog-GFP (lower) of the suspension culture over time. Scale
bars = 100μm (day 0), 200μm (days 3, 6), and 500μm (day 9). (C) An
RT-PCR analysis illustrating the temporal changes in the expressions of genes
associated with pluripotency (Oct3/4, nanog), immature NPCs (nestin),
post-mitotic neurons (Tuj1), and DA neurons (Lmx1a, Nurr1, TH, Pitx3).
GAPDH was used as a control. (D) A flow cytometric profile of the population
at day 9 labeled by the neural cell adhesion molecule PSA-NCAM. (E,F)
Immunocytochemistry of a sliced aggregate fixed on day 14 indicating the
presence of DA neurons (E) and astrocytes (F) in the culture. The scale bar
applies to all pictures and represents 50μm.
cyclosporine A (CsA, Wako) for immunosuppression. At 4 weeks
post-transplantation, the animals were intracardially perfused
with 4% paraformaldehyde under deep anesthesia. On the day of
sacrifice, blood samples were collected from each animal 1 hour
after the final injections of the test drugs or CsA. These samples
were sent to SRL, Inc. (Tokyo, Japan) for measurement of the
blood concentrations of these drugs.
REVERSE TRANSCRIPTION-POLYMERASE CHAIN REACTION (RT-PCR)
Total RNA was extracted using an RNeasy Plus Mini kit (Qiagen),
and reverse transcribed using the Super Script III First-Strand
Synthesis System (Invitrogen). PCRs were performed using Hot
StarTaq DNA polymerase (Qiagen). For each primer, a control
amplification reaction was performed without the addition of
reverse transcriptase. MEF was used as the other negative control.
The primer sequences and product sizes are shown in Table 1.
IMMUNOFLUORESCENCE STUDY
For the in vitro experiments, on day 14, drug-treated cell aggre-
gates were fixed in 4% paraformaldehyde, frozen and cut into
10-μm-thick slices using a microtome for immunocytochem-
istry. Following the in vivo experiments, the brains were removed
and re-fixed for two days in 4% paraformaldehyde, cryopreserved
in 30% sucrose for 3 days, frozen, and cut into 40-μm-thick
slices for immunohistochemistry. Frozen sections of the spheres
and brains were permeabilized and blocked with 0.3% Triton
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Table 1 | Summary of primers for RT-PCR.
Gene name Forward primer Reverse primer Product size
Oct3/4 CCTGGGCGTTCTCTTTGGAAAGG GTAGGGAGGGCTTCGGGCACTT 263
Nanog AGCAATGGTCTGATTCAGAAGGGCTC AAATGCGCATGGCTTTCCCTAGTG 368
Nestin GGCTTCTCTTGGCTTTCCTGACCC GGGGGACATCCTGGGCTCTGAC 269
Tuj1 GGGCCAAGTTCTGGGAGGTCATC GTCCAAAGGCGCCAGACCGA 198
Lmx1a CCAGAACCAGCGAGCCAAGATGA AGGCATCTGGGGTGGGGTGAG 238
Nurr1 GCGCTTAGCATACAGGTCCAACCC CCTTGAGCCCGTGTCTCTCTGTGA 212
TH TCCGGGCTTCTCTGACCAGGC GCCAGTCCGTTCCTTCAAGAAGTGAG 280
Pitx3 GGGACGCACTAGACCTCCCTCCAT AAGCCACCTTTGCACAGCTCC 420
GAPDH CTCATGACCACAGTCCATGCCATCA TCATCATACTTGGCAGGTTTCTCCAGG 251
X-100 and 2% donkey serum in PBS(–) for 1 h at room temper-
ature, followed by overnight incubation with primary antibodies
at 4◦C. The primary antibodies used in this study included rab-
bit anti-tyrosine hydroxylase (1:400, TH;Millipore), mouse anti-
TH (1:200, Millipore), sheep anti-TH (1:400, Millipore), mouse
anti-Tubβ3 (1:1000, Tuj1; Covance), rat anti-NURR1 (1:1000,
a gift from Dr. Ono, KAN Research Institute, Kobe, Japan),
rabbit anti-Ki67 (1:1000, Novocastra: NCL-Ki67p), rabbit anti-
Caspase3 (1:500, Santa Cruz Biotechnology), rat anti-M2M6
(1:50, Developmental Studies Hybridoma Bank), mouse anti-
Nestin (1:500, Millipore), rabbit anti-Pitx3 (1:500, Chemicon),
goat anti-HNF-3β (1:500, Foxa2; Santa Cruz Biotechnology),
and mouse anti-NeuN (1:500, Chemicon). After three washes
with 0.05% Tween-20 in PBS, the samples were incubated with
Alexa Fluor-conjugated secondary antibodies at room temper-
ature for 1 h. Following three additional washes, the samples
were incubated with DAPI for nuclear staining and mounted
using Permafluor (Dako). The immunoreactive cells were visu-
alized with a confocal laser microscope (Fluoview FV1000D;
Olympus, Tokyo, Japan). To determine the percentage of posi-
tive cells for each marker, labeled cells were manually counted
for at least three independent experiments. The graft volume and
number of Ki67+/Nestin+ cells were determined by identifying
M2M6+ areas in every sixth 40-μm-thick section using the BZ-II
Analyzer software program (Keyence) and totaling the volumes
of all 240-μm-tall cylinders according to Cavalieri’s principle.
To estimate the number of immuno-reactive cells in each graft,
the cells were manually counted in every sixth section, and the
Abercrombie correction was applied (Abercrombie, 1946).
STATISTICAL ANALYSIS
The statistical analyses were performed using the GraphPad Prism
software program Ver. 5.0 b (GraphPad Software). All quantita-
tive data are presented as the mean value ± SD, and One-Way
ANOVA and Newman–Keuls post-hoc tests were used. Differences
were considered to be statistically significant for P < 0.05.
RESULTS
GENERATION OF DA NEURONS FROM MURINE iPSCs
Murine iPSCs (440A3) were induced to differentiate into DA neu-
rons via the SFEB method with the addition of FGF 8 b and Shh,
as described in Figure 1A. On day 0, dissociated iPSCs quickly re-
aggregated in each well, and these cells proliferated continuously
over 14 days in culture (Figure 1B). Along with the differenti-
ation, the expression of Nanog-GFP gradually decreased until
day 9, when it almost disappeared. The temporal changes in the
gene expression profile shown in Figure 1C clearly illustrate the
step-wise differentiation of the Oct3/4+ andNanog+ pluripotent
population on day 0 into Nestin+ immature NPCs around days
6–9 then into Tuj1+ neurons as they began to express the markers
specific for DA subtype such as Lmx1a, Nurr1, and TH.
Although DA neurons were successfully generated in our sus-
pension culture, undifferentiated iPSCs and non-neural cells
possibly remained. In order to obtain a more homogenous popu-
lation of NPCs, we used FACS to select for cells positive for PSA-
NCAM, a cell adhesion molecule that is specifically expressed on
the surface of neural cells (Bonfanti, 2006). On day 9, ∼60% of
the cells were positive for PSA-NCAM (Figure 1D). Following
FACS, PSA-NCAM+ cells were made to re-aggregate and allowed
to mature for another 5 days, then subjected to immunocyto-
chemical studies on day 14. Immunofluorescent staining of the
sliced aggregates revealed that most of the cells were TUJ1+ neu-
rons, and among them were some mesencephalic DA neurons
that simultaneously expressed TH, NURR1, FOXA2, and PITX3
(Figure 1E). Only a few (<0.1% of the total number of cells) cells
expressed GFAP, a marker for astrocytes (Figure 1F).
VPA AND E2 INCREASED DOPAMINERGIC NEURONS in vitro
First, we examined whether the test drugs, VPA, ZNS, and E2,
affected the differentiation of DA neurons in vitro. In addition to
these three drugs, GDNFwas used as a positive control since it has
been shown to support DA neurons in vitro (Young et al., 2010)
and in vivo (Sinclair et al., 1996; Yurek, 1998). Re-aggregated PSA-
NCAM+ cells were treated with these drugs for 4 days starting on
day 10. Immunocytochemistry performed on day 14 revealed that
more than 90% of the cells expressed the neuronal marker Tuj1
under all conditions (Figures 2A,B) and that 5.2 ± 1.1% of the
control cells were TH+ (Figures 2A,C). The percentage of TH+
neurons significantly increased, by ∼2-fold, when the cells were
treated with 0.01mM or 0.1mM VPA, or 10 nM E2 (12.1 ± 1.5,
11.7 ± 0.4, or 12.2 ± 2.3%, respectively). To investigate whether
this effect of VPA and E2 is mediated through the cyclic AMP
pathway or the estrogen receptor, we used an adenylate cyclase
inhibitor ddA (DeCastro et al., 2005), or an estrogen receptor
antagonist ICI, respectively. When 100μMof ddA or 2μMof ICI
were added simultaneously with 0.1mM of VPA or 10 nM of E2,
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FIGURE 2 | Differentiation of iPSCs under VPA, ZNS, and E2 treatment
in vitro. Suspension cultures of murine iPSCs (440A3) were selected for
PSA-NCAM+ neural progenitor cells on day 9, re-aggregated and then treated
for 4 days with GDNF (as a positive control), VPA, ZNS, and E2. On day 14,
the aggregates were fixed, sliced into 10-μm-thick sections and subjected to
an immunocytochemical analysis for the expressions of neuronal (Tuj1) and
dopaminergic (TH) markers. In the experiments for inhibition, ddA (100μM)
or ICI (2μM) was added to the culture medium between days 10 and 14
either alone or in combination with VPA (0.1mM) or E2 (10 nM), respectively.
(A) Representative immunofluorescent images for TH/Tuj1 in the control and
drug-treated cultures. The scale bar applies to all pictures and represents
200μm (top) and 50μm (lower). (B–D) A comparison of the number of cells
labeled for Tuj1 (B) and TH (C,D) per the total number of cells. The data are
presented as the mean ± SD. (∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001; n = 3).
respectively, for 4 days, the increase in TH+ neurons was reduced
significantly (Figure 2D). Addition of ddA or ICI alone did not
change the percentage of TH+ neurons.
In order to further characterize the TH+ neurons, we per-
formed double-labeled immunocytochemistry for the mark-
ers of midbrain DA neurons, including FOXA2, NURR1, and
PITX3 alongside TH. The percentages of TH+ FOXA2+, and
TH+NURR1+ cells significantly increased when the cells were
treated with 0.1mM of VPA compared to that observed under the
control conditions (1.00 ± 0.58% vs. 0.25 ± 0.22%, and 1.00 ±
0.70% vs. 0.37 ± 0.32%, respectively; Figure 3). There were only
a few PITX3+ cells (<0.1% of the total number of cells), most
likely because the period for differentiation was too short and
there were no supportive cytokines such as GDNF in the culture
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FIGURE 3 | Generation of midbrain DA neurons from iPSCs under
VPA and E2 treatment in vitro. On day 14, the aggregates
subjected to an immunocytochemical analysis for the expressions of
midbrain DA neuron markers. (A) Representative immunofluorescent
images of TH, FOXA2, and NURR1 in the control and drug-treated
cultures. The scale bar applies to all pictures and represents 100μm
(top) and 50μm (lower). (B,C) A comparison of the number of cells
labeled for both TH and FOXA2 (B) or TH and NURR1 (C) per the
total number of cells. The data are presented as the mean±SD.
(∗P < 0.05; n = 6).
medium. These results suggest that VPA treatment promotes DA
differentiation and the acquisition of a midbrain-like DA neuron
phenotype.
Next, we evaluated whether the drugs affected the survival of
TH+ neurons by labeling apoptotic cells for caspase 3 expression.
In control spheres, 18.0± 5.9% of TH+ neurons were also labeled
with caspase 3, indicating that 1/5 of the DA neurons were under-
going apoptosis (Figure 4). Figure 4B shows that VPA- (8.2 ±
9.0% by 0.01mM, 11.1± 9.7% by 0.1mM) and E2- (8.9± 12.9%
by 10 nM)) treatment tended to yield lower percentages of apop-
totic DA neurons; however, there were no significant differences
in the percentages of apoptotic fractions of DA neurons between
the four groups.
VPA PROMOTED NEURONAL DIFFERENTIATION OF GRAFTED NPCs
Next, we investigated whether the systemic administration of
VPA, ZNS, or E2 influenced the survival and differentiation of
DA neurons in the grafts. In this transplantation study, unsorted
cell populations (3.1 × 105 cells in two aggregates, in PBS) were
injected into the striata of intact SD rats on day 9. The rats
received intraperitoneal injections of one of the drugs and the
immunosuppressant CsA every day starting 2 days before the
transplantation and continuing until the day of sacrifice at 4
weeks. On the day of sacrifice, the blood concentration of CsA
was 3700 ± 898 ng/ml on average. The blood concentrations of
VPA, ZNS, and E2 were 158.5 ± 3.9μg/ml, 2.43 ± 0.13μg/ml,
and 1141 ± 926 pg/ml, respectively.
Double-labeled immunohistochemistry at 4 weeks post-
transplantation against Nestin (an NPC marker) and Ki67 (a
marker of proliferating cells) revealed that 15–20% of the grafted
cells were Nestin+, but again there were no statistically significant
differences (Figures 5A,B). The percentages of Ki67+ cells per
Nestin+ cells were quite low in all grafts (<0.1%), suggesting that
the Nestin+ cells were mostly quiescent or becoming post-mitotic
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FIGURE 4 | Apoptosis of iPSC-derived TH+ cells under VPA, ZNS,
and E2 treatment in vitro. On day 14, the aggregates were
subjected to an immunocytochemical analysis for dopaminergic (TH)
markers as well as caspase 3, which is expressed by apoptotic cells.
(A) Representative immunofluorescent images of TH (green) and
caspase 3 (red) in the control and drug-treated cultures. The
arrowheads indicate double-positive cells. The scale bar applies to all
pictures and represents 50μm. (B) A comparison of the number of
TH+ cells labeled for caspase 3. The data are presented as the
mean ± SD (no significant differences; n = 6).
at that time point. In contrast, immunohistochemistry against
NeuN, a mature neuronal marker, revealed that the percentage
of NeuN+ cells per the total number of cells was significantly
increased when the animals were treated with VPA (77.9 ± 5.1%
vs. 57.7± 9.4% in the control group; Figures 5A,C). These results
suggest that VPA promoted the neuronal differentiation of the
grafted NPCs.
The grafted cells were identified using immunofluorescent
staining for M2M6, which is only expressed by mouse cells and
not by the host rat cells. At 4 weeks post-transplantation, label-
ing with M2M6 revealed that the grafts in all groups survived
well, with no signs of tumor formation (Figure 6A, n = 8 in the
control group, n = 6 in the VPA, ZNS, and E2 groups). The
average estimated graft volume was smallest in the VPA-treated
animals (4.33 ± 2.14mm3) and was as large as 9.76 ± 3.19mm3
in the control group, but there were no statistically significant
differences (Figure 6B).
ENHANCED SURVIVAL OF MIDBRAIN DA NEURONS IN VPA- AND
ZNS-TREATED GRAFTS
Based on our in vitro data showing that the test drugs increased
the number of TH+ neurons, we compared the number of
TH+ neurons in the grafts of each group at 4 weeks post-
transplantation. A double-labeled immunofluorescence study
revealed that the VPA-treated grafts yielded significantly higher
numbers of TH+ cells than the control grafts (1396 ± 864 and
393 ± 311, respectively; Figures 6A,C). Only a small fraction of
total TH+ neurons co-expressed the midbrain marker FOXA2
in the control grafts (24.7 ± 9.3%). In contrast, the majority of
TH+ neurons in the VPA- and ZNS-treated grafts were FOXA2+
(81.8 ± 33.6% and 80.4 ± 21.1%, respectively). The statistical
analysis demonstrated that the number of midbrain DA neurons
(TH+FOXA2+) in the grafts were significantly increased in the
animals treated with VPA or ZNS compared to those observed
in the controls (984 ± 770, 835 ± 540, and 97 ± 76, respec-
tively; Figures 6A,D). Overall, these observations indicate that the
systemic administration of VPA and ZNS increased the yield of
midbrainDAneurons in vivo by promoting the DAdifferentiation
of the grafted NPCs.
DISCUSSION
In this study, we investigated whether VPA, ZNS, or E2 affects the
survival and differentiation of DA neurons derived from murine
iPSCs. We found that treatment with VPA at 0.1mM significantly
increased the percentage of TH+FOXA2+ and TH+NURR1+ DA
neurons derived from the iPSC-derived NPCs in vitro. In the
subsequent transplantation study, the systemic administration of
VPA and ZNS significantly improved the yield of TH+FOXA2+
DA neurons in the grafts.
Here, for the first time, we showed that a low dose of VPA
(0.01 or 0.1mM) is advantageous in promoting DA differen-
tiation from murine iPSC-derived NPCs in vitro. The positive
effects of VPA on neuronal differentiation have been demon-
strated in a previous study (Hsieh et al., 2004); however, the
effects on the differentiation of DA neurons have not been well-
documented. In a study by DeCastro et al., a short chain fatty acid
including VPA was shown to induce TH mRNA transcription in
the pheochromocytoma cell line PC12 through the cyclic AMP-
dependent signaling pathway (DeCastro et al., 2005). Our result
that simultaneous addition of an adenylate cyclase inhibitor ddA
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FIGURE 5 | Analyses of iPSC-derived transplants in animals treated with
VPA, ZNS, or E2. On day 9, aggregations of differentiated cells were injected
into the striata of intact SD rats (3.1 × 105 cells in two aggregates/tract).
The rats received intraperitoneal injections of saline, VPA, ZNS, or E2.
(A) Representative immunohistologic images of nestin (immature NPCs; red)
and Ki67 (proliferation marker; green), post-mitotic neurons (NeuN; green),
and DA neurons (TH; red). A magnified image of the boxed area is shown in
the inlet. The lower inlet displays a high magnification of the proliferating
neural precursors lining the ventricular surface as a positive control for Ki67
staining. The scale bar applies to all pictures and represents 500μm. A
comparison between each group for (B) the number of Nestin+ cells per the
total number of cells in the graft, (C) the number of NeuN+ cells per the total
number of cells in the graft. The data are presented as the mean ± SD.
(∗P < 0.05; n = 8 control, n = 6 VPA, ZNS, E2).
with 0.1mM of VPA suppressed the effects of VPA suggests that
the increased DA differentiation induced by VPA is mediated by
the cyclic AMP-dependent pathway. On the other hand, 1mM of
VPA, a moderate dose that corresponds to the therapeutic plasma
concentration (Blaheta and Cinatl, 2002), seemed to increase the
rate of apoptosis of DA neurons. This observation corroborates
the study by Hsieh in which VPA increased the apoptosis as well
as the neuronal differentiation of NPCs in a dose-dependentman-
ner (Hsieh et al., 2004). Due to the fragile nature of differentiated
DA neurons, the cytotoxic effect of 1mM of VPAmight have been
more prominent than the TH-inducing effect. VPA is also known
to be a histone deacetylase (HDAC) inhibitor, associated with the
increased transcription of a variety of factors that may contribute
to the protection of midbrain DA neurons, including free radical
scavengers, heat-shock proteins, and anti-apoptotic bcl-2 family
members (Kidd and Schneider, 2010, 2011). Therefore, the poten-
tial mechanisms of VPA may be multiple and remain unclear.
Extensive exploration is needed.
Despite the lack of noteworthy effects in vitro, ZNS adminis-
tration resulted in an increase in the yield of TH+FOXA2+ DA
neurons in the grafts. A recent study showed that ZNS supported
DA neurons in vitro via an indirect effect mediated by astro-
cytes (Asanuma et al., 2010). Asanuma et al. demonstrated that
ZNS markedly increases glutathione, a powerful anti-oxidant, in
astrocytes and acts as a neuroprotectant against oxidative stress in
6-OHDA-lesioned rats. Therefore, the absence of astrocytes in the
culture (>95% were TUJ1+ neurons) likely hindered ZNS from
exerting such beneficial effects in vitro. On the other hand, the
in vivo effects of ZNS were likely mediated by astrocytes that are
abundant in the host brain. The neuroprotective effects of ZNS
in PD model animals and the effects in enhancing TH have been
reported in several other studies (Yano et al., 2009; Sonsalla et al.,
2010; Choudhury et al., 2011). Therefore, we suggest that the sys-
temic administration of ZNS can also be an effective strategy for
increasing the yield of TH+FOXA2+ DA neurons obtained from
grafted NPCs.
In addition to VPA at a concentration of 0.01 or 0.1mM, treat-
ment with E2 at a concentration of 10 nM also resulted in a good
yield of TH+ neurons in vitro. These effects of increasing the
number of DA neurons in vitro are consistent with the previous
findings of our group and others in which E2 increased the prolif-
eration of DA progenitors through actions mediated by estrogen
receptors (Kishi et al., 2005; Díaz et al., 2009). Increased prolif-
eration induced by E2 has also been observed more generally in
the NSCs of rats (Brännvall et al., 2002) and humans (Wang et al.,
2008). Despite the favorable results obtained in vitro, the systemic
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FIGURE 6 | Analyses of iPSC-derived midbrain DA neurons in animals
treated with VPA, ZNS, or E2. (A) Representative immunohistologic
images of grafts (M2M6; green) containing DA neurons (TH; red), FOXA2
(ventral-midbrain marker; red), and TH (DA neuron marker; green). The
scale bar applies to all pictures and represents 500μm (upper) and
50μm (lower). A comparison between each group for (B) average graft
volume, (C) the number of TH+ cells per graft, and (D) the number of
TH+FOXA2+ cells (midbrain DA neurons) per graft. The data are
presented as the mean ± SD. (∗P < 0.05, ∗∗P < 0.01; n = 8 control,
n = 6 VPA, ZNS, E2).
administration of E2 resulted in a poor yield of DA neurons in the
transplants. We might have observed more TH+ cells in the grafts
if there was a more appropriate concentration for E2 administra-
tion or if we had examined the samples at a later time point rather
than at 4 weeks post-transplantation.
Approximately 20–75% of the TH+ cells in the grafts did not
express FOXA2, suggesting that they are not of the midbrain but
possibly of the forebrain subtype of DA neurons. In addition,
∼95% of the NeuN+ cells in the grafts did not express TH, indi-
cating that they are not DA but rather another type of neuron.
Although the protocol used to generate midbrain DA neurons
from iPSCs has been developing, the one used in the present study
is not yet perfect. To achieve more abundant survival of midbrain
DA neurons, further improvements in the protocol and purifica-
tion of midbrain DA progenitor cells are needed. We attempted
to transplant PSA-NCAM+ cells after FACS, which resulted in a
low survival rate of the grafted cells, particularly DA neurons (less
than 50 TH+ cells per graft under each condition). Therefore, the
method of cell sorting and recovery after sorting also needs to be
improved.
In conclusion, we herein demonstrated improved survival
and differentiation of iPSC-derived DA neurons showing a
midbrain-like phenotype following the systemic administration
of well-established anti-epileptic drugs, VPA, and ZNS. Recent
efforts in the field of stem cell therapy have primarily focused on
deriving more genuine cells of clinically relevant cell types such as
midbrain DA neurons from pluripotent stem cells. It is, however,
equally important to develop strategies to modify the microenvi-
ronment of the host brain in order to achieve the optimal results
of such therapies. Because there are so many safety issues to over-
come before pluripotent stem cells can be used for the treatment
of otherwise incurable diseases, we believe that taking advantage
of drugs that are already safely used can save valuable time in the
clinical application of stem cell technology.
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